Read More Pharma Industry News Merck KGaA to acquire SpringWorks Therapeutics in $3.9bn rare tumor expansion Find out how Merck KGaA, Darmstadt, Germany’s $3.9 billion SpringWorks acquisition is reshaping rare tumor treatment and global healthcare leadership. byPallavi MadhirajuApril 28, 2025